Skip to main content

Natera Files Additional Patent Infringement Lawsuit Against ArcherDx

NEW YORK – Natera said on Friday that it has filed a lawsuit against ArcherDx in the US District Court for the District of Delaware for allegedly infringing Natera's US Patent No. 10,731,220.

The patent is titled "Methods for Simultaneous Amplification of Target Loci" and was issued by the United States Patent and Trademark Office on Aug. 4, 2020. Natera said it is one of more than 200 patents issued or pending in its global intellectual property portfolio, including more than 60 in the field of oncology.

In its lawsuit, Natera alleges that ArcherDx's sale and use of certain cell-free DNA-based oncology products infringe on the '220 patent.

In January, Natera sued ArcherDx for allegedly infringing on a different patent number (US Patent No. 10,538,814) with the same name, and it expanded that lawsuit in April to include three additional patents: US Patent Nos. 10,557,172 and 10,597,708 (both with the same name) and US Patent No. 10,590,482, "Amplification of cell-free DNA using nested PCR."

Natera is seeking injunctive relief and monetary damages in all cases.

ArcherDx is in the midst of being acquired by Invitae in a deal worth approximately $1.4 billion.